Article 25fa pilot End User Agreement

This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) with explicit consent by the author. Dutch law entitles the maker of a short scientific work funded either wholly or partially by Dutch public funds to make that work publicly available for no consideration following a reasonable period of time after the work was first published, provided that clear reference is made to the source of the first publication of the work.

This publication is distributed under The Association of Universities in the Netherlands (VSNU)'Article 25fa implementation' pilot project. In this pilot research outputs of researchers employed by Dutch Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act are distributed online and free of cost or other barriers in institutional repositories. Research outputs are distributed six months after their first online publication in the original published version and with proper attribution to the source of the original publication.

You are permitted to download and use the publication for personal purposes. Please note that you are not allowed to share this article on other platforms, but can link to it. All rights remain with the author(s) and/or copyrights owner(s) of this work. Any use of the publication or parts of it other than authorised under this licence or copyright law is prohibited. Neither Radboud University nor the authors of this publication are liable for any damage resulting from your (re)use of this publication.

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please contact the Library through email: copyright@ubn.ru.nl, or send a letter to:

University Library
Radboud University
Copyright Information Point
PO Box 9100
6500 HA Nijmegen

You will be contacted as soon as possible.

Structure–Activity Relationship Studies on (*R*)-PFI-2 Analogues as Inhibitors of Histone Lysine Methyltransferase SETD7

Danny C. Lenstra,^[a] Eddy Damen,^[b] Ruben G. G. Leenders,^[b] Richard H. Blaauw,^[c] Floris P. J. T. Rutjes,^[a] Anita Wegert,^[b] and Jasmin Mecinović^{*,[a]}

SETD7 is a histone H3K4 lysine methyltransferase involved in human gene regulation. Aberrant expression of SETD7 has been associated with various diseases, including cancer. Therefore, SETD7 is considered a good target for the development of new epigenetic drugs. To date, few selective small-molecule inhibitors have been reported that target SETD7, the most potent being (*R*)-PFI-2. Herein we report structure–activity rela-

tionship studies on (*R*)-PFI-2 and its analogues. A library of 29 structural analogues of (*R*)-PFI-2 was synthesized and evaluated for inhibition of recombinantly expressed human SETD7. The key interactions were found to be a salt bridge and a hydrogen bond formed between (*R*)-PFI-2's NH_2^+ group and SETD7's Asp256 and His252 residue, respectively.

Introduction

Covalent posttranslational modifications on the unstructured N-terminal histone tails play an important role in regulating the activity of human genes.^[1] These modifications are introduced by ‘writers’ and, among others, include methylation, acetylation, phosphorylation, citrullination, and ubiquitination.^[2] Methylation is one of the most abundant and well-studied modifications on histones.^[3] The transfer of a methyl group from co-substrate *S*-adenosylmethionine (SAM) to lysine residues is catalyzed by histone lysine methyltransferases (KMTs).^[4] KMTs can catalyze the addition of up to three methyl groups to the ϵ -amino group of lysine residues, affording methyllysine (Kme), dimethyllysine (Kme2) and trimethyllysine (Kme3).^[5] With the exception of DOT1L, an H3K79 methyltransferase, all KMTs contain a highly conserved SET (Su(var)3–9, enhancer-of-zeste, trithorax) domain, which is responsible for their catalytic activity.^[6]

SET domain containing lysine methyltransferase 7 (SETD7, also known as SET7/9) was originally identified as a monomethylase of lysine 4 on histone 3 (H3K4).^[7] Unlike many other methyltransferases, SETD7 only monomethylates H3K4, but does not catalyze di- or trimethylation of lysine. This methylation mark (H3K4me) has a functional effect on the chromatin state resulting in activation of transcription. SETD7 has also

been found to catalyze methylation of a range of non-histone proteins, including estrogen receptor α (ER α),^[8] DNA methyltransferases 1 (DNMT1),^[9] TAF10,^[10] FoxO3,^[11] transcription factors YY1 and Pdx1,^[12] androgen receptor,^[13] ARTD1,^[14] β -catenin,^[15] and tumor suppressor p53.^[16] Recent biomedical studies revealed that SETD7 is involved in multiple signaling pathways, and its aberrant activity has been linked to various types of cancer^[17] and vascular dysfunction in patients with type 2 diabetes.^[18] The development of SETD7 small molecule inhibitors as chemical probes for studying their biological activity in cells is therefore highly desired and may lead to the development of therapeutic agents for the treatment of human diseases.^[18,19]

To date, only a few selective SETD7 inhibitors have been identified. Clinically approved antihistaminic cyproheptadine was found to inhibit SETD7-mediated methylation of H3K4 (IC₅₀ of 3.4 μM). The substrate in this study was ER α , and in vivo inhibition led to blocking of estrogen-dependent breast cancer cell growth in MCF7 cells.^[20] A structure–activity relationship study was performed, however, none of the analogues proved to be more potent than cyproheptadine.^[21] Several SAM derivatives have also been reported to inhibit SETD7 methyltransferase activity; for instance, DAAM-3 (IC₅₀ 10 μM)^[22] and DC-S239 (IC₅₀ 4.59 μM).^[23] Unfortunately, SAM-competitive inhibitors usually have poor selectivity amongst other methyltransferases due to the highly conserved SAM binding domain in the methyltransferase family. The most potent known SETD7 inhibitor (IC₅₀ = 2.0 $\pm$ 0.2 nM) is (*R*)-PFI-2 (Figure 1 b–c), while its enantiomer (*S*)-PFI-2 proved to be a very weak SETD7 inhibitor, highlighting that the stereochemistry of the amino acid side chain defines its potency.^[24] (*R*)-PFI-2 is a histone competitive inhibitor, and exhibits an inhibition potency in vitro and in cellular assays.^[24] Comparative studies demonstrated that (*R*)-PFI-2 is selective for SETD7 over 18 other human methyltransferases.

[a] D. C. Lenstra, Prof. Dr. F. P. J. T. Rutjes, Dr. J. Mecinović
Institute for Molecules and Materials, Radboud University, Heyendaalseweg
135, 6525 AJ Nijmegen (The Netherlands)
E-mail: j.mecinovic@science.ru.nl

[b] Dr. E. Damen, Dr. R. G. G. Leenders, Dr. A. Wegert
Mercachem BV, Kerkenbos 1013, 6546 BB Nijmegen (The Netherlands)

[c] Dr. R. H. Blaauw
Chiralix, Toernooiveld 100, 6525 EC Nijmegen (The Netherlands)

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/cmdc.201800242>.

Figure 1. a) SETD7-catalyzed methylation of H3K4; b) crystal structure of SETD7 (grey) in complex with (*R*)-PFI-2 (cyan) (PDB ID: 4JLG); c) structure of (*R*)-PFI-2, with sites A, B, and C for SAR exploration.

Although the structure of (*R*)-PFI-2 in complex with SETD7 has been solved (Figure 1b), no further analogues have been reported. To investigate which structural elements of (*R*)-PFI-2 are essential for effective inhibition of SETD7, we carried out a structure–activity relationship (SAR) study. We modified three distinctive moieties that have a potential to crucially contribute to the potency of (*R*)-PFI-2: 1) The amino acid side chain (Figure 1c, part A); 2) the pyrrolidine amide (Figure 1c, part B); and 3) the tetrahydroisoquinoline moiety (Figure 1c, part C).

Results and Discussion

We initiated our investigations with the synthesis of (*R*)-PFI-2 (1) and its 29 structural analogues (Scheme 1). In general, the synthesis was adapted from a published protocol,^[24] and starts from an unnatural D-amino acid; typically Boc-protected D-phenylalanine derivatives were coupled to the requisite amines using EDCI, HOBt, and DIPEA. Then the Boc group was removed with TFA in CH₂Cl₂, followed by a basic workup to afford the free amine. The sulfonyl part of the inhibitor was synthesized from various aryl bromides (Scheme 1). These aryl bromides were first reacted with benzyl mercaptan in the presence of Pd₂(dba)₃ and Xantphos to afford aryl benzyl sulfides, followed by oxidation with trichloroisocyanuric acid to yield the corresponding sulfonyl chlorides. The sulfonyl chlorides were then coupled to the free amines in the presence of triethylamine in CH₂Cl₂ to afford the desired structural analogues of (*R*)-PFI-2.

Initially, all synthesized compounds were tested for their inhibitory activity using an established matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-

Scheme 1. Syntheses of (*R*)-PFI-2 and its analogues 1–28: i) Boc₂O, NaOH in H₂O/dioxane (1:1 v/v), RT, 20 h; ii) EDCI, HOBt, DIPEA, R₂NH in CH₂Cl₂, RT, 20 h; iii) TFA/CH₂Cl₂ (1:1 v/v), RT, 2–4 h; iv) Pd₂(dba)₃, Xantphos, DIPEA, benzylmercaptan in dioxane, 100 °C, 6 h; v) benzyltrimethylammonium chloride, trichloroisocyanuric acid, Na₂CO₃ in H₂O/MeCN, 0 °C → RT, 1 h; vi) Et₃N in CH₂Cl₂, RT, 4 h. Where applicable, Boc-protected compounds were deprotected using TFA/CH₂Cl₂ (1:1 v/v).

TOF MS) assay, monitoring the monomethylation of a synthetic 21-mer histone 3 peptide mimic containing a lysine at position 4.^[25] In a typical assay, 200 nM of SETD7, 10 μM of H3K4 histone peptide, 16 μM of SAM and 10 or 100 μM of compounds 1–30 were incubated for 1 hour at 37 °C. For compounds showing >50% inhibition at 100 μM, IC₅₀ values were determined. In cases where <50% inhibition at 100 μM was observed, IC₅₀ values were not determined and this data is presented as IC₅₀ > 100 μM. Enzymatic activity of these compounds at 100 μM concentration can be found in Figure S1 in the Supporting Information (SI). Representative MALDI data of selected compounds at 10 μM are shown in Figure 2. In a control experiment without inhibitor (5% (v/v) of DMSO) nearly quantitative methylation was observed in the presence of human SETD7 (*m/z* = 2269.5) (Figure 2a). Under standard conditions, but in the presence of 10 μM of (*R*)-PFI-2 (compound 1), no methylation was observed in the MALDI spectrum (Figure 2b).

We further examined the potency of (*R*)-PFI-2 against recombinantly expressed human SETD7. Under our assay conditions, an IC₅₀ value of 138 nM was obtained for (*R*)-PFI-2 (Figure 3, compound 1), indicating very effective inhibition of SETD7 methyltransferase activity. Previously reported IC₅₀ values for (*R*)-PFI-2 were 2.0 and 55 nM, respectively;^[24, 25b] the observed difference with our measured IC₅₀ value is due to differences in employed assay and assay conditions. Representative inhibition curves can be found in SI Figure S2. Two isomers of 1, with *ortho*- (compound 2) and *para*-CF₃ (compound 3) substituents also displayed excellent inhibitory activity with IC₅₀ values of 203 and 173 nM, respectively. The potencies of ana-

Figure 2. a) Representative MALDI-TOF MS data for 200 nM SETD7, 21-mer H3K4 peptide (10 μ M), SAM (16 μ M) in 50 mM glycine pH 8.8 containing 2.5% glycerol and 5% DMSO (v/v) after 1 h at 37 $^{\circ}$ C; b) 10 μ M (*R*)-PFI-2 (compound 1); c) 10 μ M compound 9; d) 10 μ M compound 14; e) 10 μ M compound 27. Y-axes: relative abundance.

logues 4–6 bearing a methyl, chloro, or bromo functionality at the *meta*-position were evaluated next. All compounds were found to be excellent inhibitors of SETD7 with IC_{50} values ranging from 132 to 178 nM. Also compound 7, which does not contain any substituent on the phenyl ring, was found to be a good SETD7 inhibitor with an IC_{50} of 266 nM. Adding an extra fused ring, as in the naphthalene-containing compound 8, gave an IC_{50} of 145 nM, indicating that there is sufficient space available for additional functionalization. Notably, removing the entire side chain (as in glycine-based compound 9) led to rather poor inhibition with an IC_{50} of 79 μ M, implying that the aromatic ring is crucial for potency.

Next, the effect of modifications in the pyrrolidine amide side chain was investigated (Figure 1c, part B). The analysis of the crystal structure of (*R*)-PFI-2 as co-crystal with SETD7 and SAM (PDB ID: 4JLG) illustrates that the pyrrolidine part of the inhibitor is positioned inside the lysine channel pointing towards SAM (Figure 1b). Based on this structural information, it is clear that space in this pocket is limited and that a significant increase in the size of the pyrrolidine moiety would presumably not be tolerated. Indeed, 1-adamantyl-substituted compound 10 did not show any inhibitory activity against SETD7. No significant difference in IC_{50} was observed when the five-membered ring of the pyrrolidine amide (compound 7, 266 nM) was replaced by a four-membered ring: an IC_{50} of 290 nM was obtained for azetidine derived analogue 11. By slightly increasing the ring size to piperidine or morpholine amide, as in analogues 12 and 13, IC_{50} values of 1.3 and 1.9 μ M were observed, respectively. This result shows that a slight increase in ring size from five- to six-membered already leads to an approximate fivefold decrease in potency (compound 7 versus 12). Replacement of the five-membered ring with acyclic diethylamine derivative 14 resulted in a higher degree of rotational freedom, which could lead to a steric clash with SETD7's pocket; this proposition is in line with a surprisingly higher IC_{50} value of 20 μ M. An almost 10-fold lower

IC_{50} of 2.6 μ M was obtained by decreasing the size and rotational freedom in dimethylamine derivative 15. Removal of the entire pyrrolidine amide side chain (as in compound 16), resulted in the formation of an achiral compound. This significant structural change caused that 16 is no longer an inhibitor of SETD7 within limits of detection.

Finally, the importance of the tetrahydroisoquinoline rings was investigated (Figure 1c, part C). The simplest analogues 17–19, consisting of a phenyl ring, either unsubstituted or with fluorine on the *meta* or *para* position, did not significantly inhibit SETD7 methyltransferase activity, indicating the essential role of the tetrahydroisoquinoline scaffold of (*R*)-PFI-2 in inhibition of SETD7. IC_{50} values of >100 μ M were observed for several heteroatom-substituted analogues 20–22, containing for instance a planar or nonplanar heterocyclic system. To investigate the importance of the fluorine substituent, we synthesized analogue 23, which has an IC_{50} value of 532 nM; this is an approximate twofold increase with respect to fluorine-containing compound 7 (IC_{50} =266 nM). Approximately 10% inhibition of methyltransferase activity was observed in the presence of 100 μ M of compound 24, an analogue of 7 that has the positively charged quaternary ammonium group (under physiological conditions) replaced by a neutral methylene group of equal size (SI Figure S1). This result demonstrates that the positively charged NH_2^+ of (*R*)-PFI-2 is involved in two interactions with SETD7, namely as a salt bridge with Asp256 and a hydrogen bond with His252. Notably, when this nitrogen was translocated one position, as in tetrahydroquinoline 25, again no inhibition was observed, whereas for compound 26, only a poor inhibition with an IC_{50} value of 20 μ M was observed. Based on our examination of compounds 23–26, it is clearly evident that the most important contributor to the excellent potency of (*R*)-PFI-2 is the nitrogen-containing tetrahydroisoquinoline functionality. Having a benzylamine moiety instead of the cyclic structure, as in compound 27, a moderately active compound is obtained (IC_{50} =2.7 μ M). With compound 28, a formation of a salt bridge is no longer possible after changing the free amine to an amide functionality, and consequently no inhibition was observed. The two individual fragments of which the (*R*)-PFI-2 scaffold consists also showed no inhibitory activity (Figure 3, compounds 29 and 30).

Docking studies were then carried out to obtain more detailed information about the potential binding modes of various (*R*)-PFI-2 analogues (Figure 4a–f). Initially, to confirm the correct docking mode, (*R*)-PFI-2 was successfully redocked into the structure of SETD7 (RMSD=0.638 Å, Figure 4a). The ligand interaction diagram for SETD7-(*R*)-PFI-2 is shown in SI Figure S3. Compound 8 was docked into SETD7 and the binding mode of 8 was found to be similar to that of (*R*)-PFI-2 (Figure 4b). In the docked structure of 12, the piperidine group occupies the narrow lysine binding channel; although it is somewhat larger than (*R*)-PFI-2's pyrrolidine group, 12 does not noticeably clash with the protein (Figure 4c). Finally, two structures with the tetrahydroisoquinoline core were docked. Despite being a very poor inhibitor of SETD7 (10% inhibition at 100 μ M, SI Figure S1), docking of the carbon analogue 24 was successful and the apparent binding mode seems similar

Figure 3. A library of (*R*)-PFI-2 (compound 1) and its analogues 2–30, showing half-maximum inhibitory concentrations (IC₅₀ values).

to that of (*R*)-PFI-2, in spite of the absence of interactions with Asp256 and His252 (Figure 4d). In contrast, the benzylamine-derived compound **27** does have a potential to form a salt bridge with Asp256 and a hydrogen bond with His252 under physiological conditions, and docking of this molecule into SETD7 confirmed the existence of the energetically favorable salt bridge and hydrogen bond (Figure 4e).

Conclusions

A library of 29 (*R*)-PFI-2 analogues was synthesized and evaluated as SETD7 inhibitors with the aim to determine which structural features contribute to the excellent potency of (*R*)-PFI-2. Our results demonstrate that small perturbations in the pyrrolidine amide side chain, that is, piperidine amide **12** or dimethylamide **15** were tolerated relatively well, whereas substituents with more rotational freedom (e.g., diethylamide **14**)

Figure 4. Docking studies on various (*R*)-PFI-2 analogues (cyan) with SETD7 (cartoon, grey) with SAM (grey). SETD7 residues that form key interactions are shown in purple: a) Redocked structure of (*R*)-PFI-2 (compound **1**), RMSD = 0.638; b) docking of compound **8**, containing a naphthalene side chain; c) docking of compound **12**, containing a piperidine amide functionality; d) docking of carbon analogue **24**; e) docking of benzylamine-type compound **27**; f) superimposition of structures shown in panels a–e, with SETD7 surface visualization (grey).

or with increased size (e.g., adamantane **10**) were not tolerated. Substitutions on the aromatic side chain led to highly potent (*R*)-PFI-2 analogues. The key interactions between SETD7 and (*R*)-PFI-2 were identified to be a salt bridge and a hydrogen bond that are formed between SETD7's Asp256/His252 and the tetrahydroisoquinoline's NH_2^+ group of (*R*)-PFI-2. Removal or repositioning of this ammonium group resulted in analogues that were inactive (compounds **24** and **25**) or only poorly active (compound **26**), whereas a replacement of the tetrahydroisoquinoline moiety by benzylamine (as in compound **27**) resulted in a ≈ 10 -fold less potent inhibitor. It is envisioned that this study will importantly contribute to the growing field of epigenetic drug discovery.

Experimental Section

Inhibition studies: For determination of IC_{50} values, a MALDI-TOF-MS-based assay monitoring methylation of a 21-mer histone 3 peptide mimic containing a lysine at position 4 was used. Briefly, SETD7 (200 nM final concentration) was pre-incubated with compound (100% DMSO stock solution at appropriate concentration) for 5 min at 37 °C in 18 μL of 50 mM glycine pH 8.8 containing 2.5% glycerol as assay buffer. Then, 2 μL of SAM (16 μM final concentration) and 21-mer H3K4 peptide (10 μM final concentration) premixture was added to initiate the enzymatic reaction, thereby obtaining a final reaction volume of 20 μL containing 5% DMSO

(v/v). The reaction was left to incubate for an additional 1 h at 37 °C after which it was quenched by the addition of 20 μL of methanol. For MALDI-TOF MS analysis, a 2 μL aliquot from the quenched reaction mixture was mixed with 8 μL of saturated HCCA matrix (α -cyano-4-hydroxycinnamic acid, Sigma-Aldrich). From this mixture 1 μL was deposited on the MALDI plate for crystallization. Methyltransferase activity was calculated by taking the peak area of monomethylation state (including all isotopes and adducts), and is expressed relative to the reaction in which no compound was present (control experiment in which just 5% DMSO was present). The calculated activities were plotted against the corresponding compound concentrations and fitted to the Hill equation using OriginPro 2017 SR2 software (version b9.4.2.380). Each experiment was performed in triplicate.

Docking studies: The crystal structure of SETD7 in complex with (*R*)-PFI-2 and S-adenosylmethionine (SAM)^[24] was downloaded from the RCSB Protein Data Bank (PDB ID: 4JLG). The protein–ligand complex (chain A) was prepared for docking using the QuickPrep wizard in Molecular Operating Environment (MOE).^[26] All compounds to be docked were prepared using the default settings of the Wash wizard as implemented in MOE. Molecular docking was performed using Molegro Virtual Docker v6.0.^[27] The active binding site region was defined as a spherical region, which encompasses all protein within 10.0 Å of bound (*R*)-PFI-2. Both the MolDock Score [GRID] and PLANTS Score [GRID] with a grid resolution of 0.2 Å were evaluated to score and rank the five best docking poses for each compound. MolDock SE was selected as search algorithm

using its default settings. All figures were prepared with PyMOL visualization software.^[28]

Characterization of final compounds: Compound **1** (25 mg, 75% isolated yield, off-white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.51–7.46 (m, 1 H), 7.40–7.35 (m, 2 H), 7.33–7.31 (m, 2 H), 7.19 (d, *J* = 8.7, 1 H), 4.19 (t, *J* = 7.5, 1 H), 4.03 (bs, 2 H), 3.22–3.06 (m, 5 H), 2.99 (d, *J* = 7.5, 2 H), 2.86–2.75 (m, 2 H), 2.59–2.47 (m, 1 H), 1.76–1.52 (m, 4 H), 1.25 ppm (bs, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ = 168.3, 160.0, 157.5, 139.0, 138.9, 138.8, 138.7, 136.7, 133.0, 133.0, 131.3, 131.0, 130.7, 130.3, 129.0, 128.5, 128.3, 126.1, 126.1, 126.0, 126.0, 125.2, 124.1, 124.0, 124.0, 123.9, 123.4, 123.3, 122.5, 111.0, 110.8, 110.0, 55.8, 46.2, 45.8, 42.6, 42.1, 42.1, 39.9, 28.8, 28.8, 25.7, 23.8 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –62.6, –116.9 ppm; MS (ESI) *m/z* 500.0 [M+H]⁺; HRMS (ESI) found *m/z* 500.16332 [M+H]⁺, calcd for C₂₃H₂₆F₄N₃O₃S⁺ *m/z* 500.16310; [α]_D²¹ = –73.2° (CH₂Cl₂).

Compound **2** (31 mg, 83% isolated yield, white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.53–7.48 (m, 2 H), 7.33 (bs, 1 H), 7.28–7.24 (m, 3 H), 7.20 (dd, *J* = 1.7, 8.7 Hz, 1 H), 4.20 (t, *J* = 7.3 Hz, 1 H), 4.02 (s, 2 H), 3.24–3.06 (m, 5 H), 2.99 (d, *J* = 7.3 Hz, 2 H), 2.88–2.70 (m, 2 H), 2.67–2.56 (m, 1 H), 1.79–1.52 (m, 4 H), 1.26 ppm (bs, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ = 168.1, 160.0, 157.5, 139.8, 139.8, 139.8, 139.8, 139.8, 138.9, 138.8, 138.7, 129.9, 129.7, 129.4, 128.9, 128.7, 125.4, 125.3, 125.3, 125.3, 123.4, 123.4, 122.7, 111.0, 110.7, 55.7, 46.2, 45.8, 42.8, 42.4, 42.3, 39.9, 29.0, 29.0, 25.7, 23.9 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –62.53, –117.11 ppm; MS (ESI) *m/z* 500.1 [M+H]⁺; HRMS (ESI) found *m/z* 500.16353 [M+H]⁺, calcd for C₂₃H₂₆F₄N₃O₃S⁺ *m/z* 500.16310; [α]_D²¹ = –91.3° (CH₂Cl₂).

Compound **3** (35 mg, 91% isolated yield, off-white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.58 (d, *J* = 7.7 Hz, 1 H), 7.43–7.28 (m, 4 H), 7.18–7.13 (m, 1 H), 4.30 (t, *J* = 7.7 Hz, 1 H), 4.02 (s, 2 H), 3.23 (t, *J* = 6.3 Hz, 3 H), 3.18–3.00 (m, 4 H), 2.84–2.73 (m, 2 H), 2.68–2.61 (m, 1 H), 1.81–1.57 (m, 4 H), 1.24 ppm (bs, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ = 168.7, 160.0, 157.5, 139.0, 138.9, 138.7, 138.7, 134.1, 133.3, 133.2, 131.6, 129.0, 128.7, 128.6, 128.5, 127.3, 126.0, 125.9, 125.8, 123.4, 123.4, 123.1, 111.0, 110.8, 55.2, 46.0, 45.9, 42.8, 42.4, 42.4, 36.7, 30.9, 29.0, 25.8, 23.9 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –62.6, –117.1 ppm; MS (ESI) *m/z* 500.1 [M+H]⁺; HRMS (ESI) found *m/z* 500.16319 [M+H]⁺, calcd for C₂₃H₂₆F₄N₃O₃S⁺ *m/z* 500.16310; [α]_D²¹ = –74.0° (CH₂Cl₂).

Compound **4** (47 mg, 69% isolated yield, off-white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.34–7.31 (m, 1 H), 7.20 (dd, *J* = 1.8, 8.8 Hz, 1 H), 7.11 (t, *J* = 7.9 Hz, 1 H), 7.03–6.98 (m, 1 H), 6.94–6.88 (m, 2 H), 4.16 (dd, *J* = 6.7, 8.5 Hz, 1 H), 4.03 (bs, 2 H), 3.22–3.01 (m, 5 H), 2.94–2.73 (m, 4 H), 2.49–2.38 (m, 1 H), 2.27 (s, 3 H), 1.71–1.45 (m, 4 H), 1.26 ppm (bs, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ = 168.7, 160.0, 157.5, 139.1, 139.1, 138.7, 138.6, 138.0, 135.5, 130.1, 128.4, 128.3, 128.2, 127.8, 126.4, 123.4, 123.4, 111.1, 110.8, 56.2, 46.1, 45.7, 42.7, 42.2, 42.2, 40.4, 28.9, 25.7, 23.9, 21.3 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –117.2 ppm; MS (ESI) *m/z* 446.1 [M+H]⁺; HRMS (ESI) found *m/z* 446.19004 [M+H]⁺, calcd for C₂₃H₂₉FN₃O₃S⁺ *m/z* 446.19006; [α]_D²¹ = –91.1° (CH₂Cl₂).

Compound **5** (14 mg, 81% isolated yield, off-white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.32–7.29 (bs, 1 H), 7.22–7.14 (m, 3 H), 7.08–7.00 (m, 2 H), 4.19–4.13 (t, *J* = 7.4 Hz, 1 H), 4.02 (s, 2 H), 3.28–3.09 (m, 5 H), 2.91 (d, *J* = 7.4 Hz, 2 H), 2.85–2.76 (q, *J* = 6.1 Hz, 2 H), 2.66–2.56 (m, 1 H), 1.79–1.58 (m, 4 H), 1.26 ppm (bs, 1 H); ¹³C NMR (126 MHz, CDCl₃): δ = 168.4, 159.8, 157.8, 138.8, 138.8, 138.8, 137.7, 134.2, 129.7, 129.4, 128.6, 128.5, 127.7, 127.3, 123.4, 123.4, 111.0, 110.8, 55.9, 46.2, 45.9, 42.8, 42.3, 42.3, 39.9, 28.9, 28.9, 25.8, 23.9 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –117.0 ppm; MS (ESI) *m/z* 466.1

[M+H]⁺; HRMS (ESI) found *m/z* 466.13652 [M+H]⁺, calcd for C₂₂H₂₆ClFN₃O₃S⁺ *m/z* 466.13674; [α]_D²¹ = –88.9° (CH₂Cl₂).

Compound **6** (18 mg, 72% isolated yield, off-white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.35–7.29 (m, 2 H), 7.24–7.16 (m, 2 H), 7.14–7.06 (m, 2 H), 4.16 (t, *J* = 7.5 Hz, 1 H), 4.05 (s, 2 H), 3.28–3.10 (m, 5 H), 2.88 (d, *J* = 7.5 Hz, 2 H), 2.85–2.78 (m, 2 H), 2.66–2.55 (m, 1 H), 1.79–1.58 (m, 4 H), 1.26 ppm (bs, 1 H); ¹³C NMR (126 MHz, CDCl₃): δ = 168.4, 159.7, 157.8, 138.9, 138.9, 138.7, 138.6, 138.0, 132.3, 130.2, 130.0, 128.8, 128.3, 128.2, 128.2, 123.3, 123.3, 122.4, 111.0, 110.8, 55.9, 46.2, 45.9, 42.7, 42.2, 42.2, 39.8, 39.7, 29.7, 29.3, 28.7, 25.8, 23.9 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –117.1 ppm; MS (ESI) *m/z* 511.9 [M+H]⁺; HRMS (ESI) found *m/z* 510.08574 [M+H]⁺, calcd for C₂₂H₂₆BrFN₃O₃S⁺ *m/z* 510.08523; [α]_D²¹ = –50.8° (CH₂Cl₂).

Compound **7** (13 mg, 64% isolated yield, white solid): ¹H NMR (500 MHz, CDCl₃): δ = 7.33 (bs, 1 H), 7.25–7.18 (m, 4 H), 7.14–7.09 (m, 2 H), 4.16 (dd, *J* = 8.9, 6.2 Hz, 1 H), 4.02 (bs, 2 H), 3.17–2.87 (m, 7 H), 2.85–2.73 (m, 2 H), 2.44–2.39 (m, 1 H), 1.67–1.56 (m, 3 H), 1.52–1.45 (m, 1 H), 1.25 ppm (bs, 1 H); ¹³C NMR (126 MHz, CDCl₃): δ = 168.8, 160.1, 158.1, 139.2, 139.2, 139.1, 135.9, 129.8, 129.1, 128.9, 128.8, 127.5, 123.8, 123.8, 111.4, 111.2, 56.5, 46.4, 46.0, 43.2, 42.8, 42.7, 40.9, 29.4, 29.3, 26.0, 24.2 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –117.3 ppm; MS (ESI) *m/z* 432.1 [M+H]⁺; HRMS (ESI) found *m/z* 454.15748 [M+Na]⁺, calcd for C₂₂H₂₆FN₃O₃Na⁺ *m/z* 454.15766; [α]_D²¹ = –67.1° (CH₂Cl₂).

Compound **8** (25 mg, 85% isolated yield, off-white solid): ¹H NMR (500 MHz, CDCl₃): δ = 7.81–7.76 (m, 1 H), 7.73–7.68 (m, 2 H), 7.54 (bs, 1 H), 7.48–7.42 (m, 2 H), 7.25–7.21 (m, 2 H), 7.16 (dd, *J* = 8.7, 1.7 Hz, 1 H), 4.30 (t, *J* = 7.5 Hz, 1 H), 3.93–3.86 (m, 2 H), 3.26–3.14 (m, 3 H), 3.07 (dd, *J* = 7.5, 1.8 Hz, 2 H), 3.01 (t, *J* = 5.9 Hz, 2 H), 2.71–2.55 (m, 3 H), 1.70–1.50 (m, 3 H), 1.45–1.38 (m, 1 H), 1.25 ppm (bs, 1 H); ¹³C NMR (126 MHz, CDCl₃): δ = 168.8, 159.6, 157.6, 138.9, 138.9, 138.7, 138.6, 133.3, 133.2, 132.3, 128.5, 128.4, 128.2, 128.0, 127.6, 127.5, 127.4, 126.2, 125.8, 123.2, 123.2, 110.9, 110.7, 56.2, 46.1, 45.8, 42.7, 42.2, 42.2, 40.4, 28.7, 28.7, 25.7, 23.9 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –117.4 ppm; MS (ESI) *m/z* 482.1 [M+H]⁺; HRMS (ESI) found *m/z* 482.19176 [M+H]⁺, calcd for C₂₆H₂₉FN₃O₃S⁺ *m/z* 482.19136; [α]_D²¹ = –97.1° (CH₂Cl₂).

Compound **9** (18 mg, 75% isolated yield, off-white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.43 (bs, 1 H), 7.34 (dd, *J* = 8.7, 1.7 Hz, 1 H), 4.05 (s, 2 H), 3.67 (s, 2 H), 3.43 (t, *J* = 6.8 Hz, 2 H), 3.29 (t, *J* = 6.8 Hz, 2 H), 3.13 (t, *J* = 5.9 Hz, 2 H), 2.85 (t, *J* = 5.9 Hz, 2 H), 2.01–1.92 (m, 2 H), 1.90–1.81 (m, 2 H), 1.35 ppm (t, *J* = 7.3 Hz, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ = 164.7, 160.3, 157.8, 139.1, 139.1, 137.8, 137.8, 129.0, 128.8, 123.5, 123.5, 111.3, 111.0, 46.2, 45.9, 45.4, 44.3, 42.8, 42.5, 42.4, k 29.0, 25.8, 24.1 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –117.0 ppm; MS (ESI) *m/z* 342.0 [M+H]⁺; HRMS (ESI) found *m/z* 342.12923 [M+H]⁺, calcd for C₁₅H₂₂N₃O₃S⁺ *m/z* 342.12876.

Compound **10** (42 mg, 77% isolated yield, off-white solid): ¹H NMR (400 MHz, CDCl₃): δ = 7.29–7.26 (m, 1 H), 7.25–7.19 (m, 3 H), 7.13 (dd, *J* = 8.6, 1.8 Hz, 1 H), 7.09–7.02 (m, 2 H), 5.45 (bs, 1 H), 4.03 (s, 2 H), 3.77 (t, *J* = 7.0 Hz, 1 H), 3.12 (t, *J* = 5.9 Hz, 2 H), 2.95 (qd, *J* = 13.8, 7.0 Hz, 2 H), 2.83–2.76 (m, 2 H), 2.04–1.97 (m, 3 H), 1.80–1.71 (m, 6 H), 1.67–1.55 (m, 6 H), 1.26 ppm (bs, 1 H); ¹³C NMR (101 MHz, CDCl₃): δ = 168.5, 160.2, 157.7, 138.9, 138.8, 138.2, 138.1, 135.8, 129.3, 128.8, 128.7, 128.7, 128.5, 127.2, 123.5, 123.5, 111.1, 110.9, 58.6, 52.1, 42.7, 42.3, 42.3, 41.1, 39.4, 36.2, 29.3, 28.8, 28.8 ppm; ¹⁹F NMR (377 MHz, CDCl₃): δ = –116.6 ppm; MS (ESI) *m/z* 512.1 [M+H]⁺; HRMS (ESI) found *m/z* 512.23804 [M+H]⁺, calcd for C₂₈H₃₅FN₃O₃S⁺ *m/z* 512.23831; [α]_D²¹ = –19.1° (CH₂Cl₂).

Compound **11** (39 mg, 81 % isolated yield, white solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.35 (bs, J = 1.6 Hz, 1H), 7.30–7.22 (m, 4H), 7.15–7.10 (m, 2H), 4.05 (s, 2H), 3.90 (dd, J = 9.0, 6.1 Hz, 1H), 3.82–3.64 (m, 3H), 3.13 (t, J = 5.9 Hz, 2H), 3.07 (td, J = 8.9, 6.2 Hz, 1H), 2.95–2.76 (m, 4H), 2.08–1.99 (m, 1H), 1.97–1.83 (m, 1H), 1.30–1.22 ppm (m, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ = 169.2, 160.1, 157.6, 139.1, 139.0, 138.9, 138.8, 135.7, 129.4, 128.7, 128.5, 128.5, 127.2, 123.4, 123.3, 111.0, 110.8, 53.7, 49.7, 47.6, 42.8, 42.4, 42.3, 40.2, 29.0, 28.9, 15.2 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –117.2 ppm; MS (ESI) m/z 418.2 $[M+H]^+$; HRMS (ESI) found m/z 418.16006 $[M+H]^+$, calcd for $\text{C}_{21}\text{H}_{25}\text{FN}_3\text{O}_3\text{S}^+$ m/z 418.15965; $[\alpha]_{\text{D}}^{21}$ = –87.0° (CH_2Cl_2).

Compound **12** (47 mg, 96 % isolated yield, off-white solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.34–7.31 (m, 1H), 7.28–7.18 (m, 4H), 7.16–7.09 (m, 2H), 4.41 (dd, J = 7.8, 6.6 Hz, 1H), 4.02 (s, 2H), 3.36–3.26 (m, 1H), 3.26–3.17 (m, 1H), 3.10 (t, J = 5.9 Hz, 2H), 3.04–2.72 (m, 6H), 1.51–1.07 (m, 6H), 0.99–0.80 ppm (m, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ = 168.3, 160.0, 157.6, 138.9, 138.8, 138.8, 138.7, 135.5, 129.6, 128.6, 128.5, 128.5, 127.2, 123.5, 123.5, 111.2, 111.0, 53.6, 46.3, 43.1, 42.8, 42.4, 42.3, 40.9, 29.0, 29.0, 25.6, 25.1, 24.0 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –117.2 ppm; MS (ESI) m/z 446.1 $[M+H]^+$; HRMS (ESI) found m/z 446.19111 $[M+H]^+$, calcd for $\text{C}_{23}\text{H}_{29}\text{FN}_3\text{O}_3\text{S}^+$ m/z 446.19136; $[\alpha]_{\text{D}}^{21}$ = –92.0° (CH_2Cl_2).

Compound **13** (37 mg, 91 % isolated yield, light-yellow solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.34 (s, J = 7.8 Hz, 1H), 7.30–7.20 (m, 4H), 7.16–7.09 (m, 2H), 4.39 (dd, J = 9.4, 5.8 Hz, 1H), 4.03 (s, 2H), 3.47–3.28 (m, 3H), 3.28–3.07 (m, 4H), 3.04–2.64 (m, 7H), 1.25 ppm (bs, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ = 169.0, 159.8, 157.9, 139.0, 139.0, 138.9, 138.8, 135.4, 129.6, 129.0, 128.8, 128.7, 127.5, 123.4, 123.4, 111.1, 110.9, 66.2, 65.6, 53.3, 45.7, 42.8, 42.4, 42.4, 42.2, 41.0, 29.1, 29.0 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –117.3 ppm; MS (ESI) m/z 448.1 $[M+H]^+$; HRMS (ESI) found m/z 448.17145 $[M+H]^+$, calcd for $\text{C}_{22}\text{H}_{27}\text{FN}_3\text{O}_4\text{S}^+$ m/z 448.17063; $[\alpha]_{\text{D}}^{21}$ = –86.2° (CH_2Cl_2).

Compound **14** (41 mg, 85 % isolated yield, white solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.34–7.30 (m, 1H), 7.26–7.19 (m, 4H), 7.15–7.09 (m, 2H), 4.34 (dd, J = 7.7, 6.5 Hz, 1H), 4.01 (s, 2H), 3.31–3.20 (m, 1H), 3.13–3.00 (m, 3H), 2.99–2.82 (m, 4H), 2.78 (q, J = 5.2 Hz, 2H), 1.25 (bs, 1H), 0.92 (t, J = 7.1 Hz, 3H), 0.84 ppm (t, J = 7.1 Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3): δ = 169.5, 159.8, 157.9, 139.3, 139.2, 138.8, 138.7, 135.6, 129.5, 128.6, 128.5, 128.5, 127.2, 123.3, 123.3, 111.1, 110.9, 54.1, 42.8, 42.3, 42.3, 41.5, 40.9, 40.6, 29.0, 28.9, 13.7, 12.6 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –117.3 ppm; MS (ESI) m/z 434.1 $[M+H]^+$; HRMS (ESI) found m/z 434.19037 $[M+H]^+$, calcd for $\text{C}_{22}\text{H}_{29}\text{FN}_3\text{O}_3\text{S}^+$ m/z 434.19082; $[\alpha]_{\text{D}}^{21}$ = –64.5° (CH_2Cl_2).

Compound **15** (38 mg, 95 % isolated yield, off-white solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.31 (bs, 1H), 7.26–7.18 (m, 4H), 7.13–7.08 (m, 2H), 4.42 (dd, J = 7.9, 6.8 Hz, 1H), 4.03 (s, 2H), 3.11 (t, J = 5.9 Hz, 2H), 2.91 (d, J = 8.4 Hz, 2H), 2.80 (q, J = 5.7 Hz, 2H), 2.67 (s, 3H), 2.48 (s, 3H), 1.24 ppm (bs, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ = 170.3, 160.0, 157.6, 139.0, 139.0, 138.8, 138.7, 135.6, 129.3, 128.6, 128.5, 128.4, 127.2, 123.3, 123.3, 111.0, 110.7, 54.0, 42.8, 42.3, 42.3, 40.5, 36.5, 35.5, 28.9, 28.9 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –117.3 ppm; MS (ESI) m/z 406.1 $[M+H]^+$; HRMS (ESI) found m/z 406.16060 $[M+H]^+$, calcd for $\text{C}_{20}\text{H}_{25}\text{FN}_3\text{O}_3\text{S}^+$ m/z 406.16006; $[\alpha]_{\text{D}}^{21}$ = –91.1° (CH_2Cl_2).

Compound **16** (31 mg, 81 % isolated yield, off-white solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.34 (bs, 1H), 7.30–7.19 (m, 4H), 7.12–7.07 (m, 2H), 4.04 (s, 1H), 3.23 (t, J = 6.9 Hz, 1H), 3.11 (t, J = 5.9 Hz, 1H), 2.86–2.75 (m, 4H), 2.06 (bs, 1H), 1.25 ppm (bs, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ = 160.3, 157.8, 138.9, 138.9, 138.7, 138.6, 137.6, 128.8, 128.8, 128.7, 128.7, 128.5, 126.9, 123.3, 123.3, 111.1, 110.8,

44.2, 42.7, 42.3, 42.3, 35.8, 28.9, 28.9 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –116.9 ppm; MS (ESI) m/z 335.1 $[M+H]^+$; HRMS (ESI) found m/z 335.12305 $[M+H]^+$, calcd for $\text{C}_{17}\text{H}_{20}\text{FN}_2\text{O}_2\text{S}^+$ m/z 335.12295.

Compound **17** (88 mg, 88 %, white solid): ^1H NMR (500 MHz, CDCl_3): δ = 7.84–7.80 (m, 2H), 7.56–7.51 (m, 1H), 7.49–7.43 (m, 2H), 7.27–7.19 (m, 3H), 7.17–7.12 (m, 2H), 5.95–5.90 (d, J = 9.5 Hz, 1H), 4.17–4.05 (td, J = 9.5, 5.9 Hz, 1H), 3.14–3.06 (m, 1H), 3.03–2.89 (m, 3H), 2.87–2.80 (m, 1H), 2.32–2.24 (m, 1H), 1.57–1.36 ppm (m, 4H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.4, 139.9, 135.7, 132.6, 129.4, 128.8, 128.4, 127.2, 127.2, 56.0, 45.9, 45.5, 40.7, 25.6, 23.7 ppm; MS (ESI) m/z 359.0 $[M+H]^+$; HRMS (ESI) found m/z 381.12487 $[M+Na]^+$, calcd for $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_3\text{SNa}^+$ m/z 381.12433; $[\alpha]_{\text{D}}^{21}$ = –125.8° (CH_2Cl_2).

Compound **18** (94 mg, 94 % isolated yield, white solid): ^1H NMR (500 MHz, CDCl_3): δ = 7.62 (dt, J = 8.0, 1.7, 1.0 Hz, 1H), 7.51 (dt, J = 8.0, 2.5, 1.7 Hz, 1H), 7.45 (td, J = 8.0, 5.2 Hz, 1H), 7.28–7.20 (m, 4H), 7.17–7.13 (m, 2H), 6.27 (d, J = 9.7 Hz, 1H), 4.20 (ddd, J = 9.7, 8.4, 6.7 Hz, 1H), 3.23–3.11 (m, 1H), 3.07–2.94 (m, 4H), 2.45–2.36 (m, 1H), 1.68–1.42 ppm (m, 4H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.3, 163.1, 161.1, 142.4, 142.3, 135.6, 130.7, 130.7, 129.4, 128.5, 127.2, 123.0, 122.9, 119.7, 119.6, 114.5, 114.3, 56.2, 46.0, 45.7, 40.5, 25.7, 23.8 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –109.8 ppm; MS (ESI) m/z 376.9 $[M+H]^+$; HRMS (ESI) found m/z 399.11732 $[M+Na]^+$, calcd for $\text{C}_{19}\text{H}_{21}\text{FN}_2\text{O}_3\text{SNa}^+$ m/z 399.11546; Optical rotation $[\alpha]_{\text{D}}^{21}$ = –116.4° (CH_2Cl_2).

Compound **19** (78 mg, 78 % isolated yield, white solid): ^1H NMR (500 MHz, CDCl_3): δ = 7.83–7.77 (m, 2H), 7.27–7.18 (m, 3H), 7.15–7.06 (m, 4H), 6.15 (d, J = 9.8 Hz, 1H), 4.19–4.09 (m, 1H), 3.18–3.08 (m, 1H), 3.05–2.89 (m, 4H), 2.44–2.35 (m, 1H), 1.63–1.51 (m, 3H), 1.50–1.41 ppm (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.6, 166.0, 163.9, 136.2, 136.2, 135.6, 130.0, 129.9, 129.4, 128.5, 127.2, 116.0, 115.8, 56.0, 46.0, 45.7, 40.4, 25.6, 23.8 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = –105.4 ppm; MS (ESI) m/z 377.1 $[M+H]^+$; HRMS (ESI) found m/z 399.11607 $[M+Na]^+$, calcd for $\text{C}_{19}\text{H}_{21}\text{FN}_2\text{O}_3\text{SNa}^+$ m/z 399.11546; $[\alpha]_{\text{D}}^{21}$ = –96.7° (CH_2Cl_2).

Compound **20** (88 mg, 99 % isolated yield, white solid): ^1H NMR (500 MHz, CDCl_3): δ = 7.32 (d, J = 2.3 Hz, 1H), 7.30–7.19 (m, 4H), 7.17–7.11 (m, 2H), 6.89 (d, J = 8.5 Hz, 1H), 5.81 (d, J = 9.8 Hz, 1H), 4.33–4.21 (m, 4H), 4.13 (td, J = 9.5, 9.55 Hz, 1H), 3.18–3.03 (m, 2H), 3.01–2.89 (m, 3H), 2.38–2.29 (m, 1H), 1.67–1.53 (m, 3H), 1.50–1.39 ppm (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.6, 147.2, 143.2, 135.8, 132.5, 129.4, 128.4, 127.1, 120.9, 117.5, 116.8, 64.5, 64.1, 56.0, 45.9, 45.6, 40.6, 25.7, 23.8 ppm; MS (ESI) m/z 417.0 $[M+H]^+$; HRMS (ESI) found m/z 439.13019 $[M+Na]^+$, calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_5\text{SNa}^+$ m/z 439.13036. $[\alpha]_{\text{D}}^{21}$ = –106.4° (CH_2Cl_2).

Compound **21** (87 mg, 98 % isolated yield, white solid): ^1H NMR (500 MHz, CDCl_3): δ = 9.20 (s, 1H), 8.44 (dd, J = 0.6, 1.90 Hz, 1H), 8.18 (dd, J = 0.6, 8.6 Hz, 1H), 7.92 (dd, J = 1.9, 8.6 Hz, 1H), 7.23–7.14 (m, 3H), 7.14–7.09 (m, 2H), 6.21 (bs, 1H), 4.19 (dd, J = 6.4, 8.7 Hz, 1H), 3.10–2.93 (m, 3H), 2.93–2.77 (m, 2H), 2.42–2.33 (m, 1H), 1.51–1.36 (m, 3H), 1.35–1.24 ppm (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.4, 157.9, 155.4, 137.4, 135.6, 133.8, 129.4, 128.4, 127.2, 125.0, 123.9, 122.0, 56.2, 45.9, 45.6, 40.5, 25.6, 23.7 ppm; MS (ESI) m/z 416.1 $[M+H]^+$; HRMS (ESI) found m/z 438.09165 $[M+Na]^+$, calcd for $\text{C}_{20}\text{H}_{21}\text{N}_3\text{O}_3\text{S}_2\text{Na}^+$ m/z 438.09220. $[\alpha]_{\text{D}}^{21}$ = –107.9° (CH_2Cl_2).

Compound **22** (89 mg, 97 % isolated yield, white solid): ^1H NMR (500 MHz, CDCl_3): δ = 7.62–7.55 (m, 2H), 7.25–7.17 (m, 3H), 7.15–7.10 (m, 2H), 6.74 (d, J = 8.3 Hz, 1H), 5.91 (d, J = 9.9 Hz, 1H), 4.63 (t, J = 8.8 Hz, 2H), 4.16–4.06 (m, 1H), 3.29–3.09 (m, 3H), 3.05–2.88 (m,

4H), 2.38–2.30 (m, 1H), 1.60–1.50 (m, 3H), 1.47–1.40 ppm (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.8, 163.7, 135.8, 131.5, 129.4, 128.7, 128.4, 128.2, 127.1, 124.6, 108.8, 72.3, 55.9, 45.9, 45.6, 40.5, 29.0, 25.6, 23.8 ppm; MS (ESI) m/z 401.0 $[M+H]^+$; HRMS (ESI) found m/z 423.13553 $[M+Na]^+$, calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_4\text{SNa}^+$ m/z 423.13553. $[\alpha]_D^{21} = -124.2^\circ$ (CH_2Cl_2).

Compound **23** (56 mg, 99% isolated yield, off-white solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.56–7.48 (m, 2H), 7.26–7.16 (m, 3H), 7.15–7.04 (m, 3H), 4.13 (dd, J = 8.9, 6.2 Hz, 1H), 4.07 (s, 2H), 3.21–3.06 (m, 3H), 3.06–2.71 (m, 7H), 2.40–2.26 (m, 1H), 1.64–1.48 (m, 3H), 1.50–1.36 (m, 1H), 1.23 ppm (bs, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ = 168.7, 140.1, 137.8, 135.8, 135.6, 129.4, 128.4, 128.0, 127.1, 126.8, 124.5, 56.0, 47.8, 45.9, 45.6, 43.2, 40.5, 28.8, 25.7, 23.8 ppm; MS (ESI) m/z 414.1 $[M+H]^+$; HRMS (ESI) found m/z 414.18487 $[M+H]^+$, calcd for $\text{C}_{22}\text{H}_{28}\text{N}_3\text{O}_3\text{S}^+$ m/z 414.18514. $[\alpha]_D^{21} = -96.9^\circ$ (CH_2Cl_2).

Compound **24** (153 mg, 86% isolated yield, colorless oil): ^1H NMR (400 MHz, CDCl_3): δ = 7.51–7.45 (m, 2H), 7.25–7.17 (m, 3H), 7.15–7.08 (m, 3H), 5.77 (d, J = 9.6 Hz, 1H), 4.08 (td, J = 9.6, 5.9 Hz, 1H), 3.14–3.03 (m, 1H), 3.02–2.85 (m, 3H), 2.85–2.66 (m, 5H), 2.31–2.19 (m, 1H), 1.78 (p, J = 3.3 Hz, 4H), 1.58–1.32 ppm (m, 4H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.6, 142.6, 137.9, 136.7, 135.8, 129.4, 129.4, 128.4, 127.8, 127.1, 124.2, 55.9, 45.8, 45.4, 40.7, 29.5, 29.3, 25.6, 23.8, 22.7, 22.7 ppm; MS (ESI) m/z 413.1 $[M+H]^+$; HRMS (ESI) found m/z 435.17130 $[M+Na]^+$, calcd for $\text{C}_{23}\text{H}_{28}\text{O}_3\text{N}_2\text{SNa}^+$ m/z 435.17183. $[\alpha]_D^{21} = -92.7^\circ$ (CH_2Cl_2).

Compound **25** (32 mg, 79% isolated yield, light-yellow oil): ^1H NMR (400 MHz, CDCl_3): δ = 7.30–7.23 (m, 2H), 7.19–7.09 (m, 3H), 7.09–7.02 (m, 2H), 6.27 (d, J = 8.5 Hz, 1H), 5.49 (d, J = 9.8 Hz, 1H), 3.94 (td, J = 9.8, 5.7 Hz, 1H), 3.25 (dd, J = 6.1, 5.0 Hz, 2H), 3.06–2.87 (m, 3H), 2.87–2.51 (m, 4H), 2.20–2.06 (m, 1H), 1.85–1.75 (m, 2H), 1.51–1.38 (m, 3H), 1.35–1.23 ppm (m, 1H); ^{13}C NMR (101 MHz, CDCl_3): δ = 168.1, 147.4, 135.0, 128.4, 127.9, 127.3, 126.0, 125.9, 124.1, 119.0, 111.2, 54.8, 44.8, 44.5, 40.5, 39.7, 25.9, 24.6, 22.8, 20.1 ppm; MS (ESI) m/z 414.0 $[M+H]^+$; HRMS (ESI) found m/z 436.16680 $[M+Na]^+$, calcd for $\text{C}_{22}\text{H}_{27}\text{N}_3\text{O}_3\text{SNa}^+$ m/z 436.16708; $[\alpha]_D^{21} = -134.3^\circ$ (CH_2Cl_2).

Compound **26** (62 mg, 95% isolated yield, off-white solid): ^1H NMR (500 MHz, CDCl_3): δ = 7.53 (dd, J = 8.0, 2.0 Hz, 1H), 7.46 (bs, 1H), 7.26–7.18 (m, 3H), 7.17–7.09 (m, 3H), 4.12 (dd, J = 9.2, 6.0 Hz, 1H), 4.02 (q, J = 16.2 Hz, 2H), 3.20–3.08 (m, 3H), 3.06–2.88 (m, 4H), 2.83 (t, J = 6.0, 2H), 2.38–2.29 (m, 1H), 1.64–1.35 ppm (m, 4H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.6, 140.2, 137.3, 136.5, 135.7, 129.7, 129.4, 128.4, 127.1, 125.2, 124.7, 56.0, 47.9, 45.9, 45.5, 43.2, 40.6, 29.2, 25.6, 23.8 ppm; MS (ESI) m/z 414.1 $[M+H]^+$; HRMS (ESI) found m/z 414.18545 $[M+H]^+$, calcd for $\text{C}_{22}\text{H}_{28}\text{N}_3\text{O}_3\text{S}^+$ m/z 414.18514; $[\alpha]_D^{21} = -107.9^\circ$ (CH_2Cl_2).

Compound **27** (35 mg, 87% isolated yield, light-yellow solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.56 (dd, J = 8.0, 1.8 Hz, 1H), 7.51–7.46 (m, 1H), 7.42 (dd, J = 9.4, 1.8 Hz, 1H), 7.26–7.17 (m, 3H), 7.16–7.08 (m, 2H), 4.19 (dd, J = 8.5, 6.6 Hz, 1H), 3.94 (s, 2H), 3.14 (dd, J = 13.0, 6.1 Hz, 1H), 3.10–2.99 (m, 2H), 3.00–2.84 (m, 2H), 2.50–2.36 (m, 1H), 1.71–1.54 (m, 3H), 1.54–1.41 ppm (m, 1H); ^{13}C NMR (126 MHz, CDCl_3): δ = 168.4, 161.0, 159.0, 140.5, 140.5, 135.6, 135.2, 135.1, 129.5, 129.5, 129.4, 128.5, 127.2, 123.1, 123.0, 114.3, 114.1, 56.2, 46.1, 45.7, 40.5, 40.0, 39.9, 25.7, 23.8 ppm; ^{19}F NMR (377 MHz, CDCl_3): δ = -116.5 ppm; MS (ESI) m/z 406.1 $[M+H]^+$; HRMS (ESI) found m/z 406.16057 $[M+H]^+$, calcd for $\text{C}_{20}\text{H}_{25}\text{FN}_3\text{O}_3\text{S}^+$ m/z 406.16006; $[\alpha]_D^{21} = -82.2^\circ$ (CH_2Cl_2).

Compound **28** (69 mg, 75% isolated yield, white solid): ^1H NMR (500 MHz, $[\text{D}_6]\text{DMSO}$): δ = 8.39 (s, 1H), 8.14 (s, 1H), 7.95 (d, J =

8.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 2H), 7.58 (s, 1H), 7.28–7.09 (m, 4H), 4.10 (t, J = 7.6 Hz, 1H), 3.24–3.15 (m, 1H), 2.92 (dt, J = 6.9, 11.5 Hz, 1H), 2.88–2.66 (m, 4H), 1.71–1.60 (m, 1H), 1.52–1.45 ppm (m, 3H); ^{13}C NMR (126 MHz, $[\text{D}_6]\text{DMSO}$): δ = 168.0, 167.1, 143.5, 137.8, 137.0, 129.7, 128.6, 128.3, 127.1, 126.7, 56.1, 46.0, 45.6, 38.6, 25.2, 23.8 ppm; MS (ESI) m/z 402.0 $[M+H]^+$; HRMS (ESI) found m/z 424.13147 $[M+Na]^+$, calcd for $\text{C}_{20}\text{H}_{23}\text{N}_3\text{O}_4\text{SNa}^+$ m/z 424.13070; $[\alpha]_D^{21} = -91.7^\circ$ (CH_2Cl_2).

Compound **29** (20 mg, 99% isolated yield, TFA salt, white solid): ^1H NMR (500 MHz, CD_3OD): δ = 7.67 (d, J = 1.5 Hz, 1H), 7.57 (dd, J = 9.2, 1.6 Hz, 1H), 4.47 (s, 2H), 3.57 (t, J = 6.3 Hz, 2H), 3.23 ppm (t, J = 6.3 Hz, 2H); ^{13}C NMR (126 MHz, CD_3OD): δ = 160.0, 158.0, 145.1, 145.0, 135.4, 135.3, 122.0, 122.0, 120.3, 120.1, 110.9, 110.7, 40.7, 39.3, 39.2, 24.5, 24.5 ppm; ^{19}F NMR (377 MHz, MeOD): δ = -77.0 (CF_3COO^-), -118.1 ppm; MS (ESI) m/z 231.1 $[M+H]^+$; HRMS (ESI) found m/z 231.06035 $[M+H]^+$, calcd for $\text{C}_9\text{H}_{12}\text{FN}_2\text{O}_2\text{S}^+$ m/z 231.05922.

Compound **30** (943 mg, 80% isolated yield, yellow solid): ^1H NMR (400 MHz, CDCl_3): δ = 7.32–7.26 (m, 2H), 7.25–7.18 (m, 3H), 3.71 (t, J = 7.2 Hz, 1H), 3.52–3.43 (m, 1H), 3.42–3.29 (m, 2H), 2.95 (dd, J = 13.1, 7.2 Hz, 1H), 2.84–2.75 (m, 2H), 1.86–1.60 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3): δ = 173.1, 137.9, 129.3, 128.4, 126.7, 55.2, 46.0, 45.8, 43.0, 25.9, 24.0 ppm. MS (ESI) m/z 219.0 $[M+H]^+$; HRMS (ESI) found m/z 241.13149 $[M+Na]^+$, calcd for $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_2\text{Na}^+$ m/z 241.13168.

Acknowledgements

We thank the Netherlands Organization for Scientific Research (NWO, NCI-TA grant 731.015.202) for funding.

Conflict of interest

The authors declare no conflict of interest.

Keywords: (R)-PFI-2 • epigenetics • histone lysine methyltransferase • SETD7 • structure–activity relationships

- [1] A. J. Bannister, T. Kouzarides, *Cell Res.* **2011**, *21*, 381–395.
- [2] K. A. Gelato, W. Fischle, *Biol. Chem.* **2008**, *389*, 353–363.
- [3] E. L. Greer, Y. Shi, *Nat. Rev. Genet.* **2012**, *13*, 343–357.
- [4] C. Martin, Y. Zhang, *Nat. Rev. Mol. Cell Biol.* **2005**, *6*, 838–849.
- [5] K. Hyun, J. Jeon, K. Park, J. Kim, *Exp. Mol. Med.* **2017**, *49*, e324.
- [6] M. Wong, P. Polly, T. Liu, *Am. J. Cancer Res.* **2015**, *5*, 2823–2837.
- [7] K. Nishioka, S. Chuikov, K. Sarma, H. Erdjument-Bromage, C. D. Allis, P. Tempst, D. Reinberg, *Genes Dev.* **2002**, *16*, 479–489.
- [8] K. Subramanian, D. Jia, P. Kapoor-Vazirani, D. R. Powell, R. E. Collins, D. Sharma, J. Peng, X. Cheng, P. M. Vertino, *Mol. Cell* **2008**, *30*, 336–347.
- [9] P. O. Esteve, H. G. Chin, J. Benner, G. R. Feehery, M. Samaranayake, G. A. Horwitz, S. E. Jacobsen, S. Pradhan, *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 5076–5081.
- [10] A. Kouskouti, E. Scheer, A. Staub, L. Tora, I. Talianidis, *Mol. Cell* **2004**, *14*, 175–182.
- [11] D. R. Calnan, A. E. Webb, J. L. White, T. R. Stowe, T. Goswami, X. Shi, A. Espejo, M. T. Bedford, O. Gozani, S. P. Gygi, A. Brunet, *Aging* **2012**, *4*, 462–479.
- [12] W. J. Zhang, X. N. Wu, T. T. Shi, H. T. Xu, J. Yi, H. F. Shen, M. F. Huang, X. Y. Shu, F. F. Wang, B. L. Peng, R. Q. Xiao, W. W. Gao, J. C. Ding, W. Liu, *Sci. Rep.* **2016**, *6*, 21718.
- [13] L. Gaughan, J. Stockley, N. Wang, S. R. McCracken, A. Treumann, K. Armstrong, F. Shaheen, K. Watt, I. J. McEwan, C. Wang, R. G. Pestell, C. N. Robson, *Nucleic Acids Res.* **2011**, *39*, 1266–1279.

- [14] I. Kassner, A. Andersson, M. Fey, M. Tomas, E. Ferrando-May, M. O. Hot-tiger, *Open Biol.* **2013**, *3*, 120173.
- [15] C. Shen, D. Wang, X. Liu, B. Gu, Y. Du, F. Z. Wei, L. L. Cao, B. Song, X. Lu, Q. Yang, Q. Zhu, T. Hou, M. Li, L. Wang, H. Wang, Y. Zhao, Y. Yang, W. G. Zhu, *FASEB J.* **2015**, *29*, 4313–4323.
- [16] J. K. Kurash, H. Lei, Q. Shen, W. L. Marston, B. W. Granda, H. Fan, D. Wall, E. Li, F. Gaudet, *Mol. Cell* **2008**, *29*, 392–400.
- [17] a) J. Zhou, M. Xie, Y. Shi, B. H. Luo, G. H. Gong, J. N. Li, J. P. Wang, W. J. Zhao, Y. Zi, X. Y. Wu, J. F. Wen, *Oncol. Rep.* **2015**, *34*, 111–120; b) Y. Zhang, J. Liu, J. Lin, L. Zhou, Y. Song, B. Wei, X. Luo, Z. Chen, Y. Chen, J. Xiong, X. Xu, L. Ding, Q. Ye, *Oncotarget* **2016**, *7*, 9859–9875.
- [18] F. Paneni, S. Costantino, R. Battista, L. Castello, G. Capretti, S. Chiandotto, G. Scavone, A. Villano, D. Pitocco, G. Lanza, M. Volpe, T. F. Luscher, F. Cosentino, *Circ. Cardiovasc. Genet.* **2015**, *8*, 150–158.
- [19] a) H. U. Kaniskan, M. L. Martini, J. Jin, *Chem. Rev.* **2018**, *118*, 989–1068; b) H. Ü. Kaniskan, K. D. Konze, J. Jin, *J. Med. Chem.* **2015**, *58*, 1596–1629; c) H. Ü. Kaniskan, J. Jin, *Curr. Opin. Chem. Biol.* **2017**, *39*, 100–108.
- [20] Y. Takemoto, A. Ito, H. Niwa, M. Okamura, T. Fujiwara, T. Hirano, N. Handa, T. Umehara, T. Sonoda, K. Ogawa, M. Tariq, N. Nishino, S. Dan, H. Kagechika, T. Yamori, S. Yokoyama, M. Yoshida, *J. Med. Chem.* **2016**, *59*, 3650–3660.
- [21] T. Fujiwara, K. Ohira, K. Urushibara, A. Ito, M. Yoshida, M. Kanai, A. Tanatani, H. Kagechika, T. Hirano, *Bioorg. Med. Chem.* **2016**, *24*, 4318–4323.
- [22] H. Niwa, N. Handa, Y. Tomabechi, K. Honda, M. Toyama, N. Ohsawa, M. Shirouzu, H. Kagechika, T. Hirano, T. Umehara, S. Yokoyama, *Acta Crystallogr. Sect. D* **2013**, *69*, 595–602.
- [23] F. Meng, S. Cheng, H. Ding, S. Liu, Y. Liu, K. Zhu, S. Chen, J. Lu, Y. Xie, L. Li, R. Liu, Z. Shi, Y. Zhou, Y. C. Liu, M. Zheng, H. Jiang, W. Lu, H. Liu, C. Luo, *J. Med. Chem.* **2015**, *58*, 8166–8181.
- [24] D. Barsyte-Lovejoy, F. Li, M. J. Oudhoff, J. H. Tatlock, A. Dong, H. Zeng, H. Wu, S. A. Freeman, M. Schapira, G. A. Senisterra, E. Kuznetsova, R. Marcellus, A. Allali-Hassani, S. Kennedy, J. P. Lambert, A. L. Couzens, A. Aman, A. C. Gingras, R. Al-Awar, P. V. Fish, B. S. Gerstenberger, L. Roberts, C. L. Benn, R. L. Grimley, M. J. Braam, F. M. Rossi, M. Sudol, P. J. Brown, M. E. Bunnage, D. R. Owen, C. Zaph, M. Vedadi, C. H. Arrowsmith, *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 12853–12858.
- [25] a) D. C. Lenstra, A. H. K. Al Temimi, J. Mecnović, *Bioorg. Med. Chem. Lett.* **2018**, *28*, 1234–1238; b) K. Guitot, T. Drujon, F. Burlina, S. Sagan, S. Beaupierre, O. Pamard, R. H. Dodd, C. Guillou, G. Bolbach, E. Sachon, D. Guianvarc'h, *Anal. Bioanal. Chem.* **2017**, *409*, 3767–3777.
- [26] *Molecular Operating Environment (MOE)*, 2013.08; Chemical Computing Group ULC, 1010 Sherbooke Street West, Suite #910, Montreal, QC, H3A 2R7 (Canada), **2018**, <https://www.chemcomp.com/>.
- [27] *Molegro Virtual Docker v6.0*, Qiagen, <https://www.qiagenbioinformatics.com/>.
- [28] *PyMOL Molecular Graphics System*, Educational Version 1.74, Schrödinger, LLC, <https://pymol.org/>.

Manuscript received: April 12, 2018
Revised manuscript received: May 23, 2018
Accepted manuscript online: June 5, 2018
Version of record online: June 25, 2018